

Uncertainties from James Lind Alliance Priority Setting Partnership in Multiple Sclerosis, published July 2013																							
Identifier	Title of uncertainty	Source of uncertainty 1	Why is there uncertainty? 1	Rank of question by the PSp	What is person's age? 1	Which types of treatments? 1	Which types of treatments? 2	Which types of treatments? 3	Which types of treatments? 4	Which types of treatments? 5	Which types of treatments? 6	Which types of treatments? 7	Which types of treatments? 8	Which types of treatments? 9	Which types of treatments? 10	Which types of treatments? 11	Original uncertainty	References to reliable up-to-date systematic reviews as the time of the PSp	Systematic reviews in preparation at the time of the PSp	Systematic reviews that needed updating or extending at the time of the PSp	Ongoing controlled trials at the time of the PSp	Which outcomes should be measured? 9	
15683	Which treatments are effective to slow, stop or reverse the accumulation of disability associated with Multiple Sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	1	Any age	Mixed or complex	Exercise	Environmental	Drug	Education and training	Dist	Complementary therapies	Physical therapies	Psychological therapies	Vaccines and biologicals	Multiple Sclerosis Ranked 1 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 10 patients, 21 carers and 11 clinicians	Ho D, Xu Z, Dong S, Zheng H, Zhou H, Wang Y, Zhang S, Luffmann S, Phipps G. Experimental for relapsing-remitting Multiple Sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009897. DOI: 10.1002/4618188.CD009897.pub2; La Marra L, Vacchi L, Di Pasquale C, Ebner D, Rovaris M, Frachon S, Phipps G. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD008181. DOI: 10.1002/4618188.CD008181.pub2; Marashli H, Rosa F, Vacchi L, Rovaris M, Capor R, Com G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD009127. DOI: 10.1002/4618188.CD009127.pub2; Ho D, Zhou H, Han Y, Wang L, Wu X, Wang S, Dong S, Zheng H, Wang L, Jang L, Wang L. Rituximab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD009127. DOI: 10.1002/4618188.CD009127.pub2; Pardo J, Galán J, Santal A, Simó S, Mendi S, Di Pascual C, Gálvez J, Nájera R. For relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD007621. DOI: 10.1002/4618188.CD007621.pub2; Phipps G, Di Pasquale C, Vacchi L, Rovaris M, Frachon S, Beecher D, Santal A. Immunomodulation and immunosuppression for multiple sclerosis: a robust meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD009833. DOI: 10.1002/4618188.CD009833.pub2; Ho D, Han Y, Gao X, Dong S, Chi L, Fang Z, Wu S. Lefunolam for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010475. DOI: 10.1002/4618188.CD10475.pub2.	Brown BA, Frawley BM, Hean R, Kagan S, La Marra L, Phipps G. Experimental for relapsing-remitting Multiple Sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD008181. DOI: 10.1002/4618188.CD008181.pub2; Casassa L, Cascia D, Galati I. Plasma exchange for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD009480. DOI: 10.1002/4618188.CD009480; Fang C, Zheng H, Han Z, Liu L, Wang J. Sulindazole for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD009643. DOI: 10.1002/4618188.CD009643.pub2.	de Vries L, Mayall LM, Lovell R. Chlorzoxazone for multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD004978. DOI: 10.1002/4618188.CD004978.pub2; Phipps G. Interferon Beta for Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD006642. DOI: 10.1002/4618188.CD006642; Roman M, Chappert A, Pozzoli L, Cristean E. Interferon Beta to Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006643. DOI: 10.1002/4618188.CD006643.pub2.	Numbair Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (NIRS006) NCT01601606 Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study NCT01545070 Cognitive Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis NCT01503070	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs		
15684	How can multiple sclerosis be prevented?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	2	Any age	Exercise	Environmental	Mixed or complex	Dist	Education and training	Drug	Psychological therapy	Physical therapies	Complementary therapies	Vaccines and biologicals	Multiple Sclerosis Ranked 2 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 18 patients, 8 carers and 7 clinicians					Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome (D-Lay-MS) NCT01781768 Does-related effects of vitamin D3 on immune responses in patients with clinically isolated syndrome (SISAD) NCT01728662	Incidence of multiple sclerosis, adverse effects or complications, acceptability to patients or carers, health related quality of life, and costs	
15685	Which treatments are effective for fatigue in people with Multiple Sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	3	Any age	Mixed or complex	Environmental	Exercise	Education and training	Psychological therapy	Dist	Drug	Complementary therapies	Physical therapies	Vaccines and biologicals	Multiple Sclerosis Ranked 3 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 18 patients, 8 carers and 9 clinicians	Fryer RM, Waldall M, Spinks R, Rowell D, Newman S. Cbamirine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD007200. DOI: 10.1002/4618188.CD007200; Payne C, Wilson PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD009427. DOI: 10.1002/4618188.CD009427.pub2.	Helen M, Reilly MG, van Vlietgen ERF, Port JD, Rowland D. Exercise therapy for fatigue in multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009596. DOI: 10.1002/4618188.CD009596.			TREAFMS-E (RCTN0235262) Treating Fatigue in Multiple Sclerosis: Aortic Stenting Using TREP AFMS NCT01766202 Treating Fatigue in Multiple Sclerosis: Cognitive behavioural therapy. TREAFMS-C (RCTN0683714)	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs	
15686	How can people with multiple sclerosis be best supported to lead 'meaningful' lives?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	4	Any age	Education and training										Multiple Sclerosis Ranked 4 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 6 patients, 1 carer and 4 clinicians.	Khan T, Ananya B, Kasalingam J. Transcranial magnetic stimulation with multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD009598. DOI: 10.1002/4618188.CD009598; Wainor O, Kilian S, Dolan B, Maloney JE, Vennart P, Paster T. Community-based self-management programs for improving participation in the activities in older adults with chronic conditions (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD009597. DOI: 10.1002/4618188.CD009597; Coulter A, Frawley VA, Eccles A, Ryan S, Shepper D, Phipps G. Personalized care planning for adults with chronic or long-term health conditions (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD009523. DOI: 10.1002/4618188.CD009523; Carter NV, Labowitz NA, Devin MP, Edelman AJ, Peters M, Wood-Baker S, Smith BJ. Consumer guidelines for chronic disease management (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010096. DOI: 10.1002/4618188.CD10096.				de Jongh T, Gurot J, Gurot J, Volkovskaya V, Car J, Auer S. Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD007469. DOI: 10.1002/4618188.CD007469.pub2.	Examining the effects of a HealthSelf self-management intervention for Multiple Sclerosis NCT01527724 MyHealth-based Stress Reduction in Multiple Sclerosis (MS) NCT01341901	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs
15687	Does early treatment with aggressive disease-modifying drugs improve the prognosis for people with multiple sclerosis?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	5	Any age	Drug										Multiple Sclerosis Ranked 5 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 7 patients, 3 carers and 4 clinicians	Ho D, Xu Z, Dong S, Zheng H, Zhou H, Wang Y, Zhang S, Luffmann S, Phipps G. Experimental for relapsing-remitting Multiple Sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009897. DOI: 10.1002/4618188.CD009897.pub2.				Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome (D-Lay-MS) NCT01781768 Does-related effects of vitamin D3 on immune responses in patients with clinically isolated syndrome (SISAD) NCT01728662	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs	
15688	Is vitamin D supplementation an effective disease-modifying treatment for multiple sclerosis?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	6	Any age	Drug										Multiple Sclerosis Ranked 6 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients, 3 carers and 1 clinician					Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs		
15689	Which treatments are effective to improve mobility for people with multiple sclerosis?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	7	Any age	Exercise	Mixed or complex	Environmental	Dist	Education and training	Drug	Psychological therapy	Physical therapies	Complementary therapies	Vaccines and biologicals	Multiple Sclerosis Ranked 7 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 6 patients	Pharis RBP, Sawmanham N, Harvey LA. Focus interventions for the treatment and prevention of contractures (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD009331. DOI: 10.1002/4618188.CD009331.	Kalaitzi CM, Harvey LA, Herbert RD, Ananya B, Lorne NB, Schir R, Bovee S. Interventions for the treatment and prevention of contractures. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008462. DOI: 10.1002/4618188.CD008462.pub2.			Wanin D. A-delta-treatment for relapsing-remitting multiple sclerosis: an efficacy, randomized, double-blind, placebo-controlled clinical trial - ITADMS. <a href="https://www.clinicaltrials.gov/ct2/show/study?term=ITADMS&amp;rank=1">https://www.clinicaltrials.gov/ct2/show/study?term=ITADMS&amp;rank=1</a> ; Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome (D-Lay-MS) NCT01781768 Vitamin D Supplementation in Multiple Sclerosis NCT01490592	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs	
15690	Which treatments are effective to improve cognition in people with multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	8	Any age	Environmental	Mixed or complex	Exercise	Education and training	Dist	Drug	Complementary therapies	Psychological therapies	Physical therapies	Vaccines and biologicals	Multiple Sclerosis Ranked 8 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients, 3 carers and 2 clinicians	Ho D, Zhou H, Gao X, Han Z, Wu S, Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD008792. DOI: 10.1002/4618188.CD008792.pub2; Nair R, Ferguson H, Stark L, Lincze ML. Memory rehabilitation for people with multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD008784. DOI: 10.1002/4618188.CD008784.pub2; Road-Crafting EM. HP/Theran P. Neuro-psychological rehabilitation for multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD009131. DOI: 10.1002/4618188.CD009131.pub2.	Ho D, Zhou H, Gao X, Han Z, Wu S, Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD008792. DOI: 10.1002/4618188.CD008792.pub2; Nair R, Ferguson H, Stark L, Lincze ML. Memory rehabilitation for people with multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD008784. DOI: 10.1002/4618188.CD008784.pub2; Road-Crafting EM. HP/Theran P. Neuro-psychological rehabilitation for multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD009131. DOI: 10.1002/4618188.CD009131.pub2.			Walking While Talking: The Effect of Dong Two Things at Once in Individuals With Multiple Sclerosis NCT01975923 Memorabilia Intervention for Multiple Sclerosis (MEMS) (ISRCTN183039) Randomized controlled trial of Cognitive Rehabilitation in Multiple Sclerosis (REACTIV) NCT01207056	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs	
15691	Which treatments are effective for pain in people with multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	9	Any age	Environmental	Exercise	Mixed or complex	Drug	Dist	Psychological therapy	Education and training	Physical therapies	Complementary therapies	Vaccines and biologicals	Multiple Sclerosis Ranked 9 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 6 patients and 1 carer	MuMead ED, Midani A, Eschenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD008146. DOI: 10.1002/4618188.CD008146.pub2.	Cui Y, Zhuhan L, Mochizuki M, Lee MS, Wang J, Hui J. Aspirin for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006910. DOI: 10.1002/4618188.CD006910; AcadMed MB, Jensen MP, Patterson DR, Lynch SJ, Montgomery GH. Clinical hypnosis for chronic pain in adults (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD009161. DOI: 10.1002/4618188.CD009161	Srinivas S, Dary S, Moore RA, McDougal JL, Vissers JCM. The treatment of chronic painful conditions in adults. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007771. DOI: 10.1002/4618188.CD007771; O'Connor NE, Ward BM, Marston L, O'Connor NE. Low frequency transcranial magnetic stimulation increases for chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD008038. DOI: 10.1002/4618188.CD008038.pub2.			Management of pain-changes in multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs	
15692	Is physiotherapy effective in reducing disability in people with multiple sclerosis?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	10	Any age	Exercise										Multiple Sclerosis Ranked 10 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients, 1 carer and 4 clinicians	Ananya B, Khan P, La Marra L, Demattos M, Wade DT. Non-pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD009074. DOI: 10.1002/4618188.CD009074.pub2.				Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs		
15693	Are complementary therapies effective in slowing, stopping or reversing of disability associated with multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified		Any age		Complementary therapies									This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 6 patients and 1 carer	Cui Y, Zhuhan L, Mochizuki M, Lee MS, Wang J, Hui J. Aspirin for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006910. DOI: 10.1002/4618188.CD006910.				Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or reading health or social care services, health related quality of life, and costs		

15687	Are supplements beneficial for people with multiple sclerosis and what supplements are most effective to treat multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Diet					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patients and 1 clinician	Jagannath VA, Fatorowicz Z, Acsikn GV, Robak EW, Wharron L, Haines D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD009432. DOI: 10.1002/46188.CD009432.pub2.			Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15684	Can an accurate prognosis of multiple sclerosis be achieved as a predictor of relapse, disability, symptoms and life style changes and response to treatment?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Diagnostic					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 22 patients, 9 carers and 1 clinician				Progression of symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15684	Can exercise have an effect on biomarkers associated with multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Exercise					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers and 2 clinicians				Change in biomarkers, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15683	Can multiple sclerosis be prevented in relatives and family members of people with multiple sclerosis?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Mixed or complex					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients and 1 carer				Incidence of multiple sclerosis, adverse effects or complications, acceptability to patients or carers, health related quality of life, and costs
15684	Can vitamin D prevent multiple sclerosis?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Any age	Drug					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 7 patients, 3 carers and 1 clinician	Dia JK, Salam RA, Lassi ZS, Bhatta ZA. Food fortification with calcium and vitamin D. Impact on health outcomes (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD009201. DOI: 10.1002/46188.CD009201.pub2.	Jagannath VA, Fatorowicz Z, Acsikn GV, Robak EW, Wharron L. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD009422. DOI: 10.1002/46188.CD009422.pub2.		Incidence of multiple sclerosis, adverse effects or complications, acceptability to patients or carers, health related quality of life, and costs
15685	Does supplementation of vitamin D in pregnant women and women feeding babies prevent multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Drug					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 1 carer and 1 clinician	De Regil LM, Palacios C, Ansary A, Kilar R, Pe'ra-Rosa JF, Haines D supplementation for women during pregnancy. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008873. DOI: 10.1002/46188.CD008873.pub2.	Alte SK, Balgobin OD, Che E, Moll R. Supplementation with vitamin A for breastfeeding women for improving outcomes for the mother and baby (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD009647. DOI: 10.1002/46188.CD009647.pub2.	Jagannath VA, Fatorowicz Z, Acsikn GV, Robak EW, Wharron L. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD009422. DOI: 10.1002/46188.CD009422.pub2.	Incidence of multiple sclerosis, adverse effects or complications, acceptability to patients or carers, health related quality of life, and costs
15687	How and when can multi-disciplinary teams best advise and provide standard treatments for people with multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Service delivery					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients and 1 carer				Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15688	How can a more accurate early diagnosis of multiple sclerosis be achieved?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Diagnostic					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 5 carers and 4 clinicians				Diagnostic accuracy of multiple sclerosis, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15682	How can magnetic resonance imaging (MRI) scanning improve the prognosis of multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Diagnostic					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients and 1 carer	La Mantia L, Viazoli L, Di Piantoni C, Elvers O, Rovaris M, Prineas D. Figure 0. Evidence base for secondary progressive multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD009131. DOI: 10.1002/46188.CD009131.pub3.	Rajja J, Romanc M, Clappors A, Parronzo C, Chitwre E. Evidence base for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006643. DOI: 10.1002/46188.CD006643.pub3.	Rajja J, Romanc M, Clappors A, Parronzo C, Chitwre E. Evidence base for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006643. DOI: 10.1002/46188.CD006643.pub3.	Progression of symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15688	How can integrative medical neurophysiology (PML) be diagnosed and treated effectively in people with multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Drug	Diagnostic				This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient				Change in multichannel neurophysiology systems, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15687	How can quality of care by multiple sclerosis nurses in relation to diagnosis, treatment and prognosis of people with multiple sclerosis be measured and improved?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Service delivery					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients and 2 clinicians				Service improvement measures, change in diagnosis, treatment and prognosis of people with multiple sclerosis, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15688	Is cannabidiol an effective treatment for multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Drug					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients				Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15686	Is diet effective in slowing, stopping or reversing the accumulation of disability associated with multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Diet					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 15 patients, 4 carers and 4 clinicians	Parinetti M, Viazoli L, Sini S, Di Piantoni C, Bhatta Z, Figgini G. Dietary interventions for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009132. DOI: 10.1002/46188.CD009132.pub3.		Change in disability, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs	
15689	Is functional electrical stimulation (FES) an effective rehabilitation aid for treating foot drop in people with multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Devices					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient and 2 clinicians	Chardon LB, Chertanin L, Johnson M, Heston GP, Bennett MB. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD008756. DOI: 10.1002/46188.CD008756		Change in foot drop symptoms, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs	
15687	Is it possible to identify the environmental factors that could be manipulated to prevent multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Diagnostic					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carer and 2 clinicians				Incidence of multiple sclerosis, adverse effects or complications, acceptability to patients or carers, health related quality of life, and costs
15685	Is low dose interferon (LDN) effective in slowing, stopping or reversing the accumulation of disability associated with multiple sclerosis and managing the symptoms of multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Drug					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patients, 7 carers and 5 clinicians				Progression of disability symptoms, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15689	Is population screening for people with multiple sclerosis possible, available and effective for high risk groups?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Diagnostic					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 6 carers and 2 clinicians				Diagnostic accuracy of multiple sclerosis, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15682	Is regular exercise effective in slowing, stopping or reversing the accumulation of disability associated with multiple sclerosis and reducing the frequency of relapses?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Exercise					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patients, 4 carers and 2 clinicians	Huis M, Reijnen MB, van Vliet EEN, Port HVD, Kraaijenh D. Exercise therapy for fatigue in multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009596. DOI: 10.1002/46188.CD009596	Reijnen MB, Vanheek A, van Wageningen EEN, Gosselaar R, Kraaijenh D. Respiratory muscle training for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008824. DOI: 10.1002/46188.CD008824		Change in disability, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15687	Is stem cell therapy effective in the treatment of multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Vaccines and biologicals					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 10 patients, 5 carers and 2 clinicians				Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15681	Is the combination pill effective in helping to manage multiple sclerosis?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Adult	Drug					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient and 2 carers				Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15680	Is the treatment of chronic central venous insufficiency (CCVI) effective for the treatment of multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices	Surgery				This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patients, 7 carers and 2 clinicians	van Zuren EJ, Fedorowicz Z, Pucci E, Jagannath VA, Robak EW. Percutaneous transluminal angioplasty for treatment of chronic lower extremity arterial insufficiency (CCEVI) in multiple sclerosis patients. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009603. DOI: 10.1002/46188.CD009603.pub2.		Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs	
15680	What are the appropriate criteria for starting disease modifying drugs and who should prescribe them, and is this in line with guidance on reimbursement within the NHS?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Service delivery					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 10 patients and 2 clinicians				Guidelines on when to start treatment, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs
15681	What are the effects on quality of someone with multiple sclerosis and how can these effects be managed?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Education and training					This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers and 6 clinicians				Impact of career, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services, health related quality of life, and costs

15674	What are the palliative care needs of people with multiple sclerosis?	Uncertainties identified from carers' questions	Existing relevant systematic reviews are not up-to-date	Any age	Diagnostic								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carers and 3 clinicians						Domes B, Calvoent N, Curale V, McCrone P, Higgins J. Effectiveness and cost-effectiveness of home palliative care services for adults with advanced breast and their caregivers. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No. CD027760. DOI: 10.1002/14651858.CD027760.pub3	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15684	What are the side effects associated with different disease modifying drugs, including over the long term?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 1 carer and 3 clinicians	Hu D, Xu Z, Deng S, Zheng H, Zhou H, Wang L, Zhang S, Tsifoulakis for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No. CD009892. DOI: 10.1002/14651858.CD009892.pub3; Hu D, Han K, Guo X, Deng S, Zhu L, Feng Z, Wu S. Levamisole for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No. CD031047s. DOI: 10.1002/14651858.CD031047s.pub2	Shenoi BS, A, Frawna BM, Hsiao R, Kojan S, La Maria L, Phipps G. Fingolimod for relapsing remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No. CD030371. DOI: 10.1002/14651858.CD030371.	Rajas S, Revuru M, Chappot A, Parvizi C, Cristiane E. Interferon Beta for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No. CD066463. DOI: 10.1002/14651858.CD066463.pub3.	Adverse effects or complications; Management and/or change of multiple sclerosis symptoms, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs				
15670	What factors influence quality of life in people with multiple sclerosis and are the strategies that people with multiple sclerosis can adopt to improve quality of life?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Education and training								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 2 carers and 5 clinicians							Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15692	What impact does multiple sclerosis have on sexual health and which therapeutic interventions can improve this?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise	Physical therapies							This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	Xiao Y, Wang J, Luo H. Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No. CD009427. DOI: 10.1002/14651858.CD009427.pub2.					Change in sexual activity, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs		
15676	What impact does multiple sclerosis have on sexual relationships and which therapeutic interventions can improve this?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Mixed or complex								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carer and 2 clinicians	Xiao Y, Wang J, Luo H. Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No. CD009427. DOI: 10.1002/14651858.CD009427.pub2.					Change in frequency and content of sexual behaviour, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs		
15673	What impact does multiple sclerosis have on the ability of people with multiple sclerosis, and carers, to work and what interventions are helpful?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Mixed or complex	Physical therapies							This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers and 2 clinicians							Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15669	What information is of value to people with multiple sclerosis at different stages of their condition, and for their relatives and carers, and what method of delivery is best?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Education and training								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 5 carers and 6 clinicians	Klyne S, Sletten A, Khai F, Hussen C, Gordon A. Information provision for persons with multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No. CD030372. DOI: 10.1002/14651858.CD030372.	Carson RV, Lathiszewski NA, Brien MP, Eisenman AJ, Paez M, Wood-Baker A, Smith BJ. Consumer guidelines for chronic disease management (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No. CD009066. DOI: 10.1002/14651858.CD009066.	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs					
15680	What is the best way to measure the progression of disability in multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Diagnostic								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician							Progression of symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15683	What is the effect of infections on disease susceptibility, relapses and progression and does treating infections have an impact on multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Diagnostic								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 clinicians							Management and/or change of clinical signs and MS symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15663	What is the most effective and best tolerated exercise programme for people with multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Exercise								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 2 carers and 1 clinician	Hwa M, Rutledge MB, van Wageningen EE, Fort IVD, Hoekstra GJ. Exercise therapy for fatigue in multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No. CD009598. DOI: 10.1002/14651858.CD009598.	Kobayashi M, Verbeek J, van Wageningen EEH, Gosselaar R, Rutledge G. Respiratory muscle training for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No. CD008464. DOI: 10.1002/14651858.CD008464.	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs					
15678	What is the most valuable structure of healthcare, including care planning, involvement of multiple sclerosis specialists and community and practical support, for people with multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Service delivery								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient and 1 clinician							Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15675	What tools can be developed to support decision making for people with multiple sclerosis?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Any age	Service delivery								This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carers and 1 clinician							Impact of patient impact on decision making, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15688	Which therapeutic interventions are effective for cerebellar ataxia in people with multiple sclerosis?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental	Exercise	Mixed or complex	Diet	Drug	Psychological therapy	Education and training	Physical therapies	Complementary therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	SUP Robert M, Ripas Cones D, Fort Vanmeirhaeghe A, Santoro Madine C, Wang J, Figaal M, Norman Alford G, Burff Grog R. Whole-body vibration training for patients with neuromuscular disease. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No. CD009507. DOI: 10.1002/14651858.CD009507.pub2.	Hwa TE, Roehner L, Nair F, Skilton DA, Bullinger C. Exercise for improving balance in older people. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No. CD004693. DOI: 10.1002/14651858.CD004693.pub3.	Change in ataxia symptoms; management and/or change of MS symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs		
15668	Which therapeutic interventions are effective for eyelid retraction in people with multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Mixed or complex	Exercise	Environmental	Diet	Drug	Education and training	Complementary therapies	Devices	Physical therapies	Psychological therapy	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 19 patients, 2 carers and 2 clinicians	Uphuis RAC, Lam MPY, Frost C, van Schaik IN. Treatments for chronic inflammatory demyelinating polyneuropathy (CIPD): an overview of systematic reviews (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No. CD010369. DOI: 10.1002/14651858.CD010369.	Change in eye retraction; Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs			
15646	Which therapeutic interventions are effective for people with multiple sclerosis to manage bowel problems?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Exercise	Mixed or complex	Environmental	Diet	Drug	Education and training	Physical therapies	Psychological therapy	Complementary therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient and 1 clinician	Olmer M, Alexander CE. Drug treatment for faecal incontinence in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No. CD003116. DOI: 10.1002/14651858.CD003116.pub2.	Mitsuda Y, Lambert S, Norton C. Prolactin releasable bulking agents as treatment for faecal incontinence in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No. CD007959. DOI: 10.1002/14651858.CD007959.pub3.	Norton C, Cook JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No. CD002111. DOI: 10.1002/14651858.CD002111.pub1.	Management of bowel problems, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs	
15661	Which therapeutic interventions are effective to improve upper limb function in people with multiple sclerosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Any age	Mixed or complex	Environmental	Exercise	Education and training	Psychological therapy	Drug	Diet	Complementary therapies	Physical therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient and 2 clinicians					Change in movement of upper limbs; management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs
15645	Which therapeutic interventions are effective to prevent relapses in people with multiple sclerosis?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Exercise	Environmental	Education and training	Psychological therapy	Drug	Diet	Complementary therapies	Physical therapies	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 2 carers and 1 clinician	Barton JM, O'Connor PV, Hsieh M, Bayliss J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No. CD008621. DOI: 10.1002/14651858.CD008621.pub3.	Figini D, Dal Giverno C, Vassini L, Pfisterer R, Di Piero A, C. Beecher D, Sabat G. Immunomodulation and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No. CD008533. DOI: 10.1002/14651858.CD008533.pub2.	Hu D, Xu Z, Deng S, Zheng H, Zhou H, Wang L, Zhang S, Tsifoulakis for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No. CD009892. DOI: 10.1002/14651858.CD009892.pub3; Wang J, Xiao Y, Liu M, Liu J. Statins for multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No. CD008386. DOI: 10.1002/14651858.CD008386.pub3; Liu J, Wang L, Zhan SY, Xia Y. Docuzone for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No. CD001877. DOI: 10.1002/14651858.CD001877.pub3.	Caletka I, Ciucci G, Galati I. Plasma exchange for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No. CD008466. DOI: 10.1002/14651858.CD008466.	Shahshah S, A, Frawna BM, Hsiao R, Kojan S, La Maria L, Phipps G. Fingolimod for relapsing remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No. CD030372. DOI: 10.1002/14651858.CD030372.	Management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs
15664	Which therapeutic interventions are effective to treat burning and foot pain in people with multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Environmental	Exercise	Mixed or complex	Drug	Diet	Psychological therapy	Education and training	Physical therapies	Complementary therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 7 patients					Change in burning feet; symptoms, management and/or change of multiple sclerosis symptoms, adverse effects or complications, acceptability to patients or carers, time to return to work or normal activity, time in hospital and/or needing health or social care services; health related quality of life, and costs

41663	Which therapeutic interventions are effective to treat depression in people with multiple sclerosis?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental	Mixed or complex	Exercise	Education and training	Drug	Drug	Devices	Complementary therapies	Psychological therapies	Physical therapies	Vaccines and biologics	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	Koch MW, Glasberg A, Uylenthoekari M, Moller J, De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No: CD007256. DOI: 10.1002/14651858.CD007256.pub2		Change in depression; Management and/or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and/or reading health or social care services; health related quality of life; and costs	
41660	Which therapeutic interventions are effective to treat spasticity in people with multiple sclerosis?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental	Exercise	Mixed or complex	Drug	Education and training	Psychological therapies	Physical therapies	Devices	Complementary therapies	Vaccines and biologics	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	Amalya B, Khan F, La Marra L, Demerouti M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No: CD009974. DOI: 10.1002/14651858.CD009974.pub2	Pharis RRR, Srinivathan N, Henry LA. Passive movement for the treatment and prevention of contracture (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No: CD009331. DOI: 10.1002/14651858.CD009331	Change in spasticity; Management and/or change of MS symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and/or reading health or social care services; health related quality of life; and costs		
41649	Which therapeutic interventions are effective to treat tremors in people with multiple sclerosis?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Mixed or complex	Exercise	Environmental	Drug	Education and training	Drug	Complementary therapies	Devices	Psychological therapies	Physical therapies	Vaccines and biologics	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers	Bruce E, Nadeau A, Chalmers G, Collins C, Flanagan G, Zappala M. Apraxia for essential tremor (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No: CD009881. DOI: 10.1002/14651858.CD009881	Management and/or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and/or reading health or social care services; health related quality of life; and costs		
41662	Which therapeutic interventions are effective to treat vertigo in people with multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Exercise	Mixed or complex	Environmental	Drug	Education and training	Drug	Psychological therapies	Physical therapies	Complementary therapies	Devices	Vaccines and biologics	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 6 patients		Change in vertigo; management and/or change of MS symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and/or reading health or social care services; health related quality of life; and costs		
41647	Which therapeutic interventions including catwalkers are effective for people with multiple sclerosis to manage bladder problems?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Exercise	Environmental	Education and training	Drug	Drug	Devices	Complementary therapies	Psychological therapies	Physical therapies	Vaccines and biologics	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients and 1 clinician	Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No: CD004375. DOI: 10.1002/14651858.CD004375.pub3. Glasner CMA, Laplan MCM. Urodynamic studies for management of urinary incontinence in children and adults. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No: CD003195. DOI: 10.1002/14651858.CD003195.pub2. Curtis JE, Vicent M, Hebbson GP, Wilson DJ, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No: CD004927. DOI: 10.1002/14651858.CD004927.pub3. Ayvalik RO, Hay-Smith EJC, Chou M, Pinar floor muscle training added to another active treatment versus the one active treatment alone for urinary incontinence in women (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No: CD010561. DOI: 10.1002/14651858.CD010561	Brownell-Ryals CL, Ton SL, Lee BSB, Simpson AM, Chay KR. Probiotics for preventing urinary tract infection in people with neurogenic bladder (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No: CD010723. DOI: 10.1002/14651858.CD010723. Urano E, Bala B. Surgical management of neurogenic bladder outlet obstruction in adults with neurogenic bladder dysfunction (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No: CD004927. DOI: 10.1002/14651858.CD004927.pub3. Ayvalik RO, Hay-Smith EJC, Chou M, Pinar floor muscle training added to another active treatment versus the one active treatment alone for urinary incontinence in women (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No: CD010561. DOI: 10.1002/14651858.CD010561	Management of urinary incontinence; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and/or reading health or social care services; health related quality of life; and costs	
41638	Would a vaccine to protect against Epstein Barr virus help to prevent multiple sclerosis?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Vaccines and biologics											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 6 patients, 1 carer and 1 clinician		Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs		
42197	What are the outcomes of operating on strabismus in patients with Multiple Sclerosis	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult												This or a similar uncertainty was submitted by 2 patients. This is an indicative uncertainty derived from identical or similar submissions. The following are the submissions: lack of MS awareness across wards; research on MS & shoulder surgery outcomes & patients with other long term conditions cost analysis before and after so		Using patient important measures and outcomes		
41548	Does improving nutrition and hydration help in the healing of pressure ulcers?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Any age	Drug											This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 3		Ulcer healing		
41596	For patients with Multiple Sclerosis and pressure ulcers how often should dressings be applied for pain relief?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Drug														Ulcer healing	
41545	For people at risk of developing pressure ulcers, how effective is education for lay carers in prevention of pressure ulcers including signs to look for if a pressure ulcer begins to develop?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Education and training											This submission was a variation of one which was prioritised. Priority 2/This uncertainty was also suggested for the following patients and interventions (SI: Multiple Sclerosis)			Prevention	
41542	For people who are reliant on wheelchairs how effective is repositioning in preventing pressure ulcers?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Physical therapies											This submission was a variation of one which was prioritised. Priority 2/This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 5 The uncertainty was also suggested for the following patients and interventions (with Multiple Sclerosis, SI: [aided] repositioning between chairs, being off chair/bed (where this should be done)? How does it affect ability to undertake normal activities?	Gilgus BM, Chazyoy WP, McInnes E, Kent B, Whyte AJ. Repositioning for pressure ulcer prevention in adults. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No: CD009968. DOI: 10.1002/14651858.CD009968		Prevention	
41561	For people with Multiple Sclerosis and pressure ulcers is sensory important in relation to healing?	Uncertainties identified from carers' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies											This uncertainty was also suggested for the following patients and interventions (with limited mobility)	Moore ZEH, Cowman S. Repositioning for healing pressure ulcers. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No: CD006898. DOI: 10.1002/14651858.CD006898.pub3	Michael B M, Potter D, Pughley T E. Effect size position for non-ambulant individuals with musculoskeletal and neuromuscular impairment: a systematic review. Clinical Rehabilitation 2007; 21(12): 983-94	Ulcer healing	
41561	For people with Multiple Sclerosis and pressure ulcers that won't heal, what is the best type of surgical retractor?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Service delivery	Surgery										This submission was a variation of one which was prioritised. Priority 1=10			Ulcer healing	
41564	For people with Multiple Sclerosis and pressure ulcers how often should dressings be changed?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Physical therapies														Ulcer healing	
41549	For people with Multiple Sclerosis at risk of developing pressure ulcers what is the type of bed or mattress that reduces the risk for pressure ulcers?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Devices														Value for money to the NHS	
41581	For people with Multiple Sclerosis at risk of pressure ulcers how effective is improving hydration in the prevention of pressure ulcers?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Diagnostic															Prevention
41542	For people with multiple sclerosis or spinal injury who work with specialist clinicians how effective is preventing pressure ulcers than working with generalists?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Diagnostic												This submission was a variation of one which was prioritised. Priority 2/This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 2 The uncertainty was also suggested for the following patients and interventions (with Multiple Sclerosis, SI: [aided] repositioning between chairs, being off chair/bed (where this should be done)?			Prevention
41540	For people with pressure ulcers and Multiple Sclerosis is bed rest (electronic) to manage heel?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Devices											This uncertainty was also suggested for the following patients and interventions (Managing patients with limited mobility)			Quality of life	
41563	For people with pressure ulcers and Multiple Sclerosis who have been advised to keep moving, is bed rest to treat these ulcers?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Physical therapies											This submission was a variation of one which was prioritised. Priority 7			Adverse events	
41547	For wheelchair users with pressure ulcers, how effective is bed rest in promoting ulcer healing?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Any age	Physical therapies											This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 3. This uncertainty was also suggested for the following patients and interventions (Managing patients with limited mobility)			Ulcer healing	
41547	For wheelchair users with Multiple Sclerosis at risk of pressure ulcers and with coxide what is the best way of preventing pressure ulcers or callus?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices											This uncertainty was also suggested for the following patients and interventions (best way of preventing design/pressure relief)	McInnes E, Jermol-Bassi A, Ball-Ster BEA, Dunlop JC, Cuban N. Support surfaces for pressure ulcer prevention. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No: CD007736. DOI: 10.1002/14651858.CD007736.pub4		Prevention	
41567	How effective are dressings in the prevention of pressure ulcers?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Any age	Devices											This submission was a variation of one which was prioritised. Priority 3/This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 2 The uncertainty was also suggested for the following patients and interventions (hydrocolloid dressings) People with multiple sclerosis	Moore ZEH, Webster J. Dressings and topical agents for preventing pressure ulcers. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No: CD009362. DOI: 10.1002/14651858.CD009362		Prevention	

